Ana Fernandez-Teijeiro
Overview
Explore the profile of Ana Fernandez-Teijeiro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
365
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Daw S, Claviez A, Kurch L, Stoevesandt D, Attarbaschi A, Balwierz W, et al.
JAMA Oncol
. 2025 Jan;
PMID: 39745682
Importance: The current standard-of-care salvage therapy in relapsed/refractory classic Hodgkin lymphoma (cHL) includes consolidation high-dose chemotherapy (HDCT)/autologous stem cell transplant (aSCT). Objective: To investigate whether presalvage risk factors and fludeoxyglucose-18...
2.
Ramirez M, Pujol R, Minguillon J, Bogliolo M, Persico I, Cavero D, et al.
Am J Hematol
. 2024 Nov;
100(2):272-284.
PMID: 39562502
Fanconi anemia (FA) is a rare genetic disease characterized by high phenotypic and genotypic heterogeneity, and extreme chromosome fragility. To better understand the natural history of FA, identify genetic risk...
3.
Damek A, Kurch L, Franke F, Attarbaschi A, Beishuizen A, Cepelova M, et al.
Sci Rep
. 2024 Jun;
14(1):14591.
PMID: 38918503
Hypodense volumes (HDV) in mediastinal masses can be visualized in a computed tomography scan in Hodgkin lymphoma. We analyzed staging CT scans of 1178 patients with mediastinal involvement from the...
4.
Juan-Ribelles A, Bautista F, Canete A, Rubio-San-Simon A, Alonso-Saladrigues A, Hladun R, et al.
Clin Transl Oncol
. 2024 Apr;
26(9):2351-2359.
PMID: 38600340
Introduction: ECLIM-SEHOP platform was created in 2017. Its main objective is to establish the infrastructure to allow Spanish participation into international academic collaborative clinical trials, observational studies, and registries in...
5.
Franke F, Damek A, Steglich J, Kurch L, Hasenclever D, Georgi T, et al.
Pediatr Blood Cancer
. 2023 May;
70(8):e30421.
PMID: 37243889
Background: Rebound thymic hyperplasia (RTH) is a common phenomenon caused by stress factors such as chemotherapy (CTX) or radiotherapy, with an incidence between 44% and 67.7% in pediatric lymphoma. Misinterpretation...
6.
Mauz-Korholz C, Landman-Parker J, Fernandez-Teijeiro A, Attarbaschi A, Balwierz W, Bartelt J, et al.
Lancet Oncol
. 2023 Mar;
24(3):252-261.
PMID: 36858722
Background: Children and adolescents with early-stage classical Hodgkin lymphoma have a 5-year event-free survival of 90% or more with vincristine, etoposide, prednisone, and doxorubicin (OEPA) plus radiotherapy, but late complications...
7.
Agulnik A, Kizyma R, Salek M, Wlodarski M, Pogorelyy M, Oszer A, et al.
Lancet Haematol
. 2022 Sep;
9(9):e645-e647.
PMID: 36055331
No abstract available.
8.
Lindsay H, Massimino M, Avula S, Stivaros S, Grundy R, Metrock K, et al.
Lancet Oncol
. 2022 Jul;
23(8):e393-e401.
PMID: 35901835
Response criteria for paediatric intracranial ependymoma vary historically and across different international cooperative groups. The Response Assessment in the Pediatric Neuro-Oncology (RAPNO) working group, consisting of an international panel of...
9.
El Moukhtari S, Garbayo E, Fernandez-Teijeiro A, Rodriguez-Nogales C, Couvreur P, Blanco-Prieto M
J Control Release
. 2022 Jun;
348:553-571.
PMID: 35705114
Embryonal tumors of the nervous system are neoplasms predominantly affecting the pediatric population. Among the most common and aggressive ones are neuroblastoma (NB) and medulloblastoma (MB). NB is a sympathetic...
10.
Canete A, Peris-Bonet R, Capocaccia R, Pardo-Romaguera E, Segura V, Munoz-Lopez A, et al.
Cancer Epidemiol
. 2022 Mar;
78:102145.
PMID: 35344745
Purpose: Linkage between clinical databases and population-based cancer registries may serve to evaluate European Reference Networks' (ERNs) activity, by monitoring the proportion of patients benefiting from these and their impact...